Wuhan City, China

2019-2023

Hydrogen and oxygen therapy approved for Covid-19

During multicentre open clinical trials, hydrogen-oxygen gas inhalation decreased the severity of the disease and breathing difficulties in patients with COVID-19 of new corona pneumonia in 2019.  This resulted in the issuance on March 3, 2020, by the Chinese National Health Commission, of the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version Seven).  

wuhan city china

Brown’s Gas (HHO) Approved by China National Medical Administration For Respiratory Diseases Specifically Covid Treatment

 

The leader of the crisis response team Zhong Nanshan in Wuhan City China prescribed Hydrogen/Oxygen gas to save thousands of lives during the 2020 epidemic.

Covid-19 causes restricted breathing, and oxygen treatment is usually to help patients breathe better.

However, patients progress from oxygen to assisted breathing with a ventilator.  This is because oxygen causes terminal oxidative stress unless the patient is put on ventilator life support.

The traditional problem is that few patients come off a ventilator alive.

The new solution using Hydrogen/Oxygen therapy to rescue patients with oxidative stress was clinically trialed in several major hospitals in China as a Covid-19 treatment.  This avoided putting patients onto ventilators and prevented organ failure.  The results from a thousand case-documented clinical trials show excellent results in patient recovery, resulting in a shorter duration of stay in the hospital.

The treatment protocol was to use an exact proportion of two parts hydrogen to one part oxygen at a rate of 3 liters per minute.  Oxygen is unable to relieve oxidative stress in the body cells as it is the cause; however, the hydrogen content of Brown’s Gas can penetrate the cell walls, and by converting back to the water, effectively washes the waste from oxidation from the cells and restores normal body function and breathing.

The hydrogen/oxygen generators used in the clinical trials are now accredited by the Chinese Government National Health Commission (the equivalent of the USA FDA) and is the official government-endorsed protocol for frontline Covid-19 treatment.

The onsite generation of hydrogen and oxygen for immediate use is entirely safe as there is no need to refill bottles and store the gases.  The Brown’s Gas Generator needs only an electrical source and distilled or de-mineralized water to produce 99.999% pure hydrogen gas onsite.  There is no longer any need for hospitals and clinics to run out of hydrogen and oxygen gas or to rely on a more expensive centralized supply.

The hydrogen and oxygen technology were first licensed to China in 1991 by Research Professor Yull Brown of Brown’s Gas fame. The Professor initially attracted the attention of the Chinese government with the demonstration of Brown’s Gas eliminating the radioactivity of hazardous radioactive waste materials.  Brown’s Gas was endorsed as the future of clean onsite energy production catalyst in combustion processes as it eliminates emissions and changes back to the water after combustion.

The Founder and CEO of YBG Group International Pty Ltd of Sydney Australia, Peter Griffiths accompanied the Professor on his visit to China in 1991.  YBG Group® has an established distribution business for Brown’s Gas® Generators manufactured in China for industrial purposes.  For background refer to HHO Generators.  With the release of the successful clinical trials using hydrogen/oxygen for personal use, YBG Group® has expanded to distribute the generators proven by the clinical trials. Available generators include a range of four models spanning hospital hydrogen onsite generation and hydrogen for home use.

YBG Group® has published the Covid-19 Clinical Trial documents in an online library.

Photo: Zhong Nanshan – 84-year-old academician Zhong Nanshan was on the brink of death and led the fight for more than 60 days on the front line of the epidemic.

During multicentre open clinical trials, hydrogen-oxygen gas inhalation decreased the severity of the disease and breathing difficulties in patients with COVID-19 of new corona pneumonia in 2019.  This resulted in the issuance on March 3, 2020, by the Chinese National Health Commission, of the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version Seven).  This version was formulated based on increased clinical manifestations and pathology of the disease and accumulated experience in diagnosis and treatment.  The protocol recognizes the up-to-date pandemic situation worldwide, which is seeing the outbreak contained domestically, to a certain extent, but on the rise overseas.  Compared with the previous version, updates have been made concerning transmission routes, case definitions, discharge criteria, and therapeutic measures. 

Excerpt From The Official Chinese National Health Commission Diagnosis and Treatment Protocol Concerning Covid Patient Treatment:

QUOTE
X. Treatment

  1. The treatment venue is determined by the severity of the disease
    1.1 Suspected and confirmed cases should be isolated and treated at designated hospitals with effective isolation, protection, and prevention conditions in place. A suspect case should be treated in isolation in a single
    Confirmed cases can be treated in the same room.
    1.2 Critical cases should be admitted to ICU as soon as possible.
    2. General treatment
    2.1 Letting patients rest in bed and strengthening support therapy; ensuring sufficient caloric intake for patients; monitoring their water and electrolyte balance to maintain internal environment stability; closely
    monitoring vital signs and oxygen saturation.
    2.2 According to patients’ conditions, monitoring blood routine results, urine routine results, c-reactive protein (CRP), biochemical indicators (liver enzyme, myocardial enzyme, renal function, etc.), coagulation function,
    arterial blood gas analysis, chest imaging, and cytokines detection if necessary.
    2.3 Timely providing effective oxygen therapy, including nasal catheter and mask oxygenation and nasal high-flow oxygen therapy. If possible, inhalation of mixed hydrogen and oxygen (H2/O2: 66.6%/33.3%) can be applied.
    UNQUOTE

From page 8 of the document:

This is the PDF of document 1.Clinical.Protocols.for.the.Diagnosis.and.Treatment.of.COVID-19.V7

For The First Time, Clinical Trials Establish The Brown’s Gas (HHO) Dosage Administration Protocol

Introduction

Few therapies, if any, have been shown to rapidly ameliorate respiratory symptoms and prevent disease progression. An important mechanism contributing to dyspnea (difficulty in breathing) and disease progression in patients with COVID-19 might be the increased work of breathing because of the heightened airway resistance. Inhalation of hydrogen/oxygen mixed gas (H2-O2) might have a role in the treatment of COVID-19 given the decreased resistance compared with room air when passing through the airways.

Clinical Trials

At the height of the epidemic in Wuhan, authorities conducted an open-label multicentred clinical trial, between January 21st and March 23rd, 2020, among patients with laboratory-confirmed COVID-19 from seven hospitals in China. The patients were aged 18–85 years and had dyspnea (difficulty in breathing) on hospital admission.

Patients in the treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min through the nasal cannula by using the Hydrogen/Oxygen Generator daily until discharge

Product brochure for machine used in the clinical trials https://hho.company/wp-content/uploads/2021/07/BrownsGas-Brochure-BYTEU-HO3.pdf )

N

Brown's Gas approved by the National Government of China.

N

Administration protocol of 3 L/min through the nasal cannula by using the Hydrogen/Oxygen Generator daily until discharge.

N

Clinical Trials documents consolidated.

Ready to Protect Yourself?

?

Get in Touch

en_USEnglish